Combined serine protease PRSS22 and CEA mRNA analysis identifies the majority of colon cancer patients that recur within 12 years.

ABSTRACT:

Introduction

Proteases play an important role in tumor progression. The predictive efficacy of proteases PRSS3 and PRSS22 mRNA levels for predicting relapse in surgically treated colon cancer (CC) patients was assessed.

Methods

mRNA expression was quantified in 371 half lymph nodes (LNs) from 121 CC patients, 77 control LNs (13 patients), 66 primary colon tumors, and 30 normal colon tissues of these patients. Patients were also stratified according to their CEA mRNA level. The occurrence of relapse following curative surgery was evaluated using the Cox regression and Kaplan-Meier survival model analyses. Protein expression was examined through immunohistochemistry.

Results

PRSS22 was superior to PRSS3 in identifying patients at risk of recurrence. Thus, high PRSS22 le

SUBMITTER: Mohamed A 

PROVIDER: S-EPMC12406016 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature